Our results show that IBD patients with active disease, while having no differences in circulating CD4+CD25+FOXP3+ Treg levels compared to healthy controls, display a significant increase of this cell type after treatment with anti-TNFα. The gene discussed is CD4; the disease is irritable bowel syndrome.